Immunovant (IMVT) Shares Outstanding (Diluted Average) (2020 - 2026)

Immunovant has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $182.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 20.35% year-over-year to $182.4 million; the trailing twelve-month figure through Mar 2026 stood at $182.4 million (up 20.35% YoY), and the FY2026 full-year result was $182.4 million, up 20.35% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $182.4 million, up from $181.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $182.4 million in Q1 2026, with the low at $109.7 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $142.8 million across 5 years, with a median of $138.1 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) climbed 24.98% — and 2023, when it increased 5.45%.
• Immunovant's Shares Outstanding (Diluted Average) stood at $128.6 million in 2022, then advanced by 5.45% to $135.6 million in 2023, then grew by 8.37% to $146.9 million in 2024, then gained by 23.54% to $181.5 million in 2025, then advanced by 0.5% to $182.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $182.4 million (Q1 2026), $181.5 million (Q4 2025), and $172.3 million (Q3 2025), per Business Quant data.